Conatus Pharmaceuticals Stock Price - CNAT

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
Level 1 Starter
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Conatus Pharmaceuticals Inc CNAT NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.556 0.00 0.00 0.00 0.556 20:00:00
Bid Price Ask Price Spread Spread % News
0.5505 0.554 0.0035 0.63% 17 -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.556 USD

Conatus Pharmaceuticals Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 18.44M 33.17M 32.98M $ 21.72M $ -14.96M -0.34 -1.23
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 0.60%

more financials information »

Conatus Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CNAT Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.660.750.45230.57512734,474,850-0.104-15.76%
1 Month0.34650.750.33290.54076553,656,3110.209560.46%
3 Months0.42590.750.23030.50292881,350,7810.130130.55%
6 Months0.35250.750.23030.46876321,076,6540.203557.73%
1 Year0.8221.070.23030.4258684926,120-0.266-32.36%
3 Years5.177.9490.23032.40731,592-4.61-89.25%
5 Years5.369.400.23033.14683,145-4.80-89.63%

Conatus Pharmaceuticals Description

Conatus Pharmaceuticals Inc is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The company is developing emricasan, an orally active pan-caspase inhibitor, for the treatment of patients with chronic liver disease. Emricasan is designed to reduce the activities of human caspases, which are enzymes that mediate inflammation and apoptosis. Conatus has also been developing CTS-2090, an orally active selective caspase inhibitor, for diseases involving inflammasome pathways.

Your Recent History
Conatus Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.